Oppenheimer Downgrades Northwest Biotherapeutics (NWBO) to Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Northwest Biotherapeutics (NWBO) Refutes Adam Feuerstein's Claims
March 12, 2014 10:15 AM EDTNorthwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted false statements and material distortions made by Adam Feuerstein in an article on Tuesday, March 11.
Feuerstein falsely accused NW Bio of manipulating its news by delaying announcement of the Hospital Exemption approval by the Paul Ehrlich Institute ("PEI," the FDA of Germany). Feuerstein's accusations were factually wrong, materially misleading and reflect a lack of knowledge on... More
Northwest Biotherapeutics (NWBO) Target Lifted to $15.10 at Summer Street
March 11, 2014 11:57 AM EDTSummer Street analyst Carol Werther reiterated a Buy rating and raised her price target on Northwest Biotherapeutics (NASDAQ: NWBO) from $10.33 to $15.10 earlier, following news yesterday Germany has approved DCVax-L, a glioblastoma multiforme (GBM) vaccine, for an early access program.
"This is very strong... More
Northwest Biotherapeutics (NWBO) Receives 'Very Strong' Endorsement, Summer Street Says
March 10, 2014 1:22 PM EDTSummer Street analyst Carol Werther maintained a Buy rating and $10.33 price target on Northwest Biotherapeutics (NASDAQ: NWBO) after the company announced this morning that Germany has approved DCVax-L, its Glioblastoma multiforme (GBM) vaccine, for an early access program. The analyst notes this allows... More
